FLGT•November 18, 2026 at 4:34 AM UTCPharmaceuticals, Biotechnology & Life Sciences

Billing Fix Lifts Collections, but Reimbursement Risk Persists

Read source article

What happened

Fulgent's recent billing software improvements have lifted collection rates, providing a modest tailwind to cash collections and potentially reducing days sales outstanding. However, the news article correctly notes that the underlying reimbursement framework remains uncertain, with the HRSA audit and DOJ inquiries still unresolved. The improvement does not address the company's largest structural risks: a single customer representing 23% of revenue and persistent GAAP operating losses. The market has reacted mildly, with the stock trading near its cash per share, reflecting skepticism about the durability of these improvements. Investors should treat this as a positive operational data point, but not a reason to change the base-case valuation.

Implication

Investors should acknowledge the billing fix as evidence of improved internal controls, which could help gross margins and cash flow. However, the fix does not change the fact that one customer accounts for 23% of revenue, and losing that relationship would be devastating. The HRSA audit and DOJ civil investigative demands continue to pose non-zero cash outflow risk. Operating losses are still large, and the market is not yet pricing in sustainable profitability. Therefore, while the news is a small positive, the investment thesis remains dependent on core diagnostics growth and disciplined spending, not on billing tweaks.

Thesis delta

The billing software fix is a minor positive that supports the execution story but does not alter the fundamental thesis. The thesis remains that FLGT trades near cash value with a growing diagnostics franchise, but concentration and reimbursement risk cap upside. No change to the POTENTIAL BUY rating, with attractive entry around $22 and trim above $32.

Confidence

Medium